Výsledky vyhledávání - "Dareen Sarhan"

Abstract LB339: PARP inhibition reprograms CD8 T cells, enhancing their function and generation of prolonged memory, leading to greater anti-tumor immune response

Autor: Wael Traboulsi, Subhadip Kundu, Pankaj Gaur, Zainab Ramlaoui, Dareen Sarhan, Nour Shobaki, Jacob Lee, Nazli Jafarzadeh, Simon T. Barry, Viia E. Valge-Archer, Vivek Verma, Seema Gupta, Samir N. Khleif

Publikováno v: Cancer Research. 83:LB339-LB339

Olaparib is the most widely studied third-generation PARP inhibitor (PARPi) in clinical practice with a significant clinical outcome in BRCA deficient tumors such as breast and ovarian cancers. However, innate and adaptive resistance in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d74ccffc53ef1961329e9c7e474a468
https://doi.org/10.1158/1538-7445.am2023-lb339

Zobrazit plný text záznamu

Abstract 2881: Proper priming of T cells is crucial for the anti-tumor effect of mPTX-35, an anti-TNFRSF25 agonist antibody

Autor: Dareen Sarhan, Lara Rabah, Vikas Tahiliani, Anh M. Trinh, Rahul R. Jasuja, Eric P. Dixon, Matthew Seavey, Vivek Verma, Seema Gupta, Samir N. Khleif

Publikováno v: Cancer Research. 82:2881-2881

TNFRSF25, also known as Death Receptor 3 (DR3), is a cell surface receptor of the tumor necrosis factor receptor superfamily (TNFRSF) which is expressed on T cells, innate lymphoid cells, and B cells. Upon binding with TL1A ligand, this co-stimulator

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d3293de0b15405d75f7d07c6aba7e1d
https://doi.org/10.1158/1538-7445.am2022-2881

Zobrazit plný text záznamu

Abstract LB217: Ascorbic acid rescues antitumor immune response by reversing hypoxia-induced CD8+T cell dysfunction

Autor: Nazli Jafarzadeh, Pankaj Gaur, Dareen Sarhan, Nour Shobaki, Wael Traboulsi, Zainab Ramlaoui, Vivek Verma, Seema Gupta, Samir N. Khleif

Publikováno v: Cancer Research. 82:LB217-LB217

Growing evidence suggests that hypoxia is one of the most important phenomena of solid tumors that supports tumor progression as well as therapeutic resistance. When T cells infiltrate the tumor microenvironment (TME), they encounter hypoxia and, in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::18695cc0e031db25609415e920922496
https://doi.org/10.1158/1538-7445.am2022-lb217

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání